Cleveland diagnostics announces agreement with quest diagnostics to expand patient access to isopsa® prostate cancer testing

Cleveland--(business wire)--cleveland diagnostics, inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced an agreement designed to expand patient access to cleveland diagnostics' novel prostate cancer test, isopsa.

DGX Ratings Summary

DGX Quant Ranking